BACKGROUND: At excitatory synapses, glutamate released from neurons is taken up by glial cells and converted to glutamine, which is cycled back to neurons. Alterations in this system are believed to play a role in the pathophysiology of bipolar disorder, but they have not been characterized in vivo. We examined the glutamine/glutamate ratio and levels of other metabolites in acute mania and schizophrenia in this exploratory study. METHODS: Data were obtained from 2 x 2 x 2 cm voxels in the anterior cingulate cortex (ACC) and parieto-occipital cortex (POC) using two-dimensional J-resolved proton magnetic resonance spectroscopy at 4 Tesla and analyzed using LCModel. Fifteen bipolar disorder patients with acute mania and 17 schizophrenia patients with acute psychosis were recruited from an inpatient unit; 21 matched healthy control subjects were also studied. Glutamine/glutamate ratio and N-acetylaspartate, creatine, choline, and myo-inositol levels were evaluated in a repeated measures design. Medication effects and relationship to demographic and clinical variables were analyzed. RESULTS: Glutamine/glutamate ratio was significantly higher in ACC and POC in bipolar disorder, but not schizophrenia, compared with healthy control subjects. N-acetylaspartate was significantly lower in the ACC in schizophrenia. Patients on and off lithium, anticonvulsants, or benzodiazepines had similar glutamine/glutamate ratios. CONCLUSIONS: The elevated glutamine/glutamate ratio is consistent with glutamatergic overactivity and/or defective neuronal-glial coupling in acute mania, although medication effects cannot be ruled out. Abnormalities in glutamatergic neurotransmission and glial cell function in bipolar disorder may represent targets for novel therapeutic interventions.
BACKGROUND: At excitatory synapses, glutamate released from neurons is taken up by glial cells and converted to glutamine, which is cycled back to neurons. Alterations in this system are believed to play a role in the pathophysiology of bipolar disorder, but they have not been characterized in vivo. We examined the glutamine/glutamate ratio and levels of other metabolites in acute mania and schizophrenia in this exploratory study. METHODS: Data were obtained from 2 x 2 x 2 cm voxels in the anterior cingulate cortex (ACC) and parieto-occipital cortex (POC) using two-dimensional J-resolved proton magnetic resonance spectroscopy at 4 Tesla and analyzed using LCModel. Fifteen bipolar disorderpatients with acute mania and 17 schizophreniapatients with acute psychosis were recruited from an inpatient unit; 21 matched healthy control subjects were also studied. Glutamine/glutamate ratio and N-acetylaspartate, creatine, choline, and myo-inositol levels were evaluated in a repeated measures design. Medication effects and relationship to demographic and clinical variables were analyzed. RESULTS:Glutamine/glutamate ratio was significantly higher in ACC and POC in bipolar disorder, but not schizophrenia, compared with healthy control subjects. N-acetylaspartate was significantly lower in the ACC in schizophrenia. Patients on and off lithium, anticonvulsants, or benzodiazepines had similar glutamine/glutamate ratios. CONCLUSIONS: The elevated glutamine/glutamate ratio is consistent with glutamatergic overactivity and/or defective neuronal-glial coupling in acute mania, although medication effects cannot be ruled out. Abnormalities in glutamatergic neurotransmission and glial cell function in bipolar disorder may represent targets for novel therapeutic interventions.
Authors: H Kishimoto; O Takazu; S Ohno; T Yamaguchi; H Fujita; H Kuwahara; T Ishii; M Matsushita; S Yokoi; M Iio Journal: Psychiatry Res Date: 1987-09 Impact factor: 3.222
Authors: Rodrigo Machado-Vieira; Marcio G Soeiro-De-Souza; Erica M Richards; Antonio L Teixeira; Carlos A Zarate Journal: World J Biol Psychiatry Date: 2013-09-02 Impact factor: 4.132
Authors: Brian P Brennan; Olga Tkachenko; Zachary J Schwab; Richard J Juelich; Erin M Ryan; Alison J Athey; Harrison G Pope; Michael A Jenike; Justin T Baker; William D S Killgore; James I Hudson; J Eric Jensen; Scott L Rauch Journal: Neuropsychopharmacology Date: 2015-02-09 Impact factor: 7.853
Authors: Juan R Bustillo; Hongji Chen; Charles Gasparovic; Paul Mullins; Arvind Caprihan; Clifford Qualls; William Apfeldorf; John Lauriello; Stefan Posse Journal: Biol Psychiatry Date: 2010-10-20 Impact factor: 13.382
Authors: David M Cochran; Elif M Sikoglu; Steven M Hodge; Richard A E Edden; Ann Foley; David N Kennedy; Constance M Moore; Jean A Frazier Journal: J Child Adolesc Psychopharmacol Date: 2015-04-28 Impact factor: 2.576
Authors: M I Atagün; E M Şıkoğlu; S S Can; G Karakaş-Uğurlu; S Ulusoy-Kaymak; A Çayköylü; O Algın; M L Phillips; C M Moore; D Öngür Journal: Schizophr Res Date: 2014-12-03 Impact factor: 4.939
Authors: Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür Journal: Neuropsychopharmacology Date: 2009-12-02 Impact factor: 7.853